35 Therapies in Phase 2 and 3 Clinical Trials Raise Hopes in Alzheimer’s Community

35 Therapies in Phase 2 and 3 Clinical Trials Raise Hopes in Alzheimer’s Community
Alzheimer's research is gaining momentum, with 27 Phase 3 and eight Phase 2 clinical trials either in progress or expected over the next five years. The good news surfaced in a revised pipeline analysis of Alzheimer’s therapies that researchers presented at the Alzheimer's Association International Conference in London. The event, which started July 16, runs through July 20. Alzheimer's patients, families, doctors and caregivers have been waiting a long time for some encouragement. It's been 14 years since U.S. and European regulators approved a new treatment. ResearchersAgainstAlzheimer's made the presentation. The global coalition of Alzheimer’s researchers is pushing for more research money and policy reform to develop effective treatments for the disease by 2025. The group is one of the organizations in the UsAgainstAlzheimer's network. "The Alzheimer's disease pipeline, marred by decades of failures and underinvestment, is due for big victories," George Vradenburg, co-founder and chairman of UsAgainstAlzheimer’s, said in a press release. "Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer's innovations will bring much-needed solutions to families in the near future." In addition to identifying therapies that ar
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *